Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD

Fig. 2

Source: Adapted from Bertoluci et al. [51]. SGLT2: sodium-glucose cotransporter 2; GLP1: glucagon-like peptide 1

Algorithm for the treatment of hyperglycemia in patients with T2DM and DKD with GFR between 30 and 60 mL/min/1.73 m2 or between 30 and 90 mL/min/1.73 m2 with albuminuria. AD: Oral antidiabetic.

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us